S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
NYSE:NVRO

Nevro - NVRO Stock Forecast, Price & News

$48.85
-1.93 (-3.80%)
(As of 08/19/2022 12:57 PM ET)
Add
Compare
Today's Range
$48.00
$49.96
50-Day Range
$40.66
$53.03
52-Week Range
$39.41
$127.97
Volume
6,139 shs
Average Volume
501,987 shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.10

Nevro MarketRank™ Forecast

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
46.5% Upside
$71.10 Price Target
Short Interest
Bearish
5.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.90) to ($1.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

1040th out of 1,119 stocks

Surgical & Medical Instruments Industry

102nd out of 111 stocks

NVRO stock logo

About Nevro (NYSE:NVRO) Stock

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on NVRO shares. Wells Fargo & Company decreased their target price on Nevro from $90.00 to $86.00 and set an "overweight" rating for the company in a research report on Thursday, August 4th. Citigroup decreased their price objective on Nevro from $78.00 to $68.00 in a report on Tuesday, May 17th. Morgan Stanley reduced their price target on shares of Nevro from $55.00 to $54.00 and set an "equal weight" rating for the company in a research report on Thursday, August 4th. StockNews.com upgraded shares of Nevro from a "sell" rating to a "hold" rating in a report on Thursday, July 21st. Finally, Truist Financial cut their price target on shares of Nevro to $45.00 in a research note on Friday, July 22nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Nevro has an average rating of "Hold" and an average price target of $71.10.

Nevro Stock Performance

Nevro stock traded up $0.13 during mid-day trading on Thursday, reaching $50.78. 296,981 shares of the company's stock were exchanged, compared to its average volume of 567,975. Nevro has a one year low of $39.41 and a one year high of $127.97. The company has a quick ratio of 5.36, a current ratio of 6.65 and a debt-to-equity ratio of 0.81. The business's fifty day simple moving average is $45.72 and its 200 day simple moving average is $56.91. The firm has a market capitalization of $1.80 billion, a PE ratio of -12.73 and a beta of 0.96.

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

Piper Sandler Trims Nevro (NYSE:NVRO) Target Price to $45.00
Morgan Stanley Lowers Nevro (NYSE:NVRO) Price Target to $54.00
Nevro (NYSE:NVRO) Shares Gap Down After Analyst Downgrade
Nevro (NVRO) Set to Announce Quarterly Earnings on Wednesday
Analysts Set Nevro Corp. (NYSE:NVRO) PT at $77.00
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Company Calendar

Last Earnings
11/07/2021
Today
8/19/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
945
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.10
High Stock Price Forecast
$97.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+45.5%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$-131,360,000.00
Pretax Margin
-35.85%

Debt

Sales & Book Value

Annual Sales
$386.90 million
Book Value
$6.50 per share

Miscellaneous

Free Float
34,397,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
0.96

Key Executives

  • Mr. D. Keith GrossmanMr. D. Keith Grossman (Age 62)
    Chairman, CEO & Pres
    Comp: $857.84k
  • Mr. Roderick H. MacLeod (Age 55)
    Chief Financial Officer
    Comp: $458.2k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 48)
    Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $437.6k
  • Ms. Niamh Louise Pellegrini (Age 55)
    Chief Commercial Officer
    Comp: $482.4k
  • Mr. Patrick Schmitz (Age 62)
    VP of Operations
  • Mr. Richard B. Carter (Age 51)
    Chief Accounting Officer
  • Ms. Julie D. Dewey (Age 61)
    Chief Corp. Communications & Investor Relations Officer
  • Mr. Michael Collier Carter (Age 50)
    VP of Global Sales
  • Mr. Jon R. Shear
    VP of Corp. Devel.
  • Ms. Lori M. Ciano (Age 59)
    Chief HR Officer













NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price forecast for 2022?

11 brokerages have issued 12 month price objectives for Nevro's stock. Their NVRO share price forecasts range from $45.00 to $97.00. On average, they predict the company's stock price to reach $71.10 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2022?

Nevro's stock was trading at $81.07 on January 1st, 2022. Since then, NVRO shares have decreased by 37.4% and is now trading at $50.78.
View the best growth stocks for 2022 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its earnings results on Sunday, November, 7th. The medical equipment provider reported ($0.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.01. The medical equipment provider had revenue of $93.21 million for the quarter, compared to analysts' expectations of $91.59 million. Nevro had a negative net margin of 35.96% and a negative trailing twelve-month return on equity of 43.73%. The company's quarterly revenue was down 14.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) EPS.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its third quarter 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $97.00 million-$101.00 million, compared to the consensus revenue estimate of $109.15 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.88%), Franklin Resources Inc. (2.76%), State Street Corp (2.29%), Principal Financial Group Inc. (1.86%), Brown Advisory Inc. (1.74%) and Credit Suisse AG (1.47%). Insiders that own company stock include Andrew H Galligan, D Keith Grossman, Doug Alleavitch, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $50.78.

How much money does Nevro make?

Nevro (NYSE:NVRO) has a market capitalization of $1.80 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131,360,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis.

How many employees does Nevro have?

The company employs 945 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.